Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00793845 | Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma | completed | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02011126 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
| withdrawn |
| Phase 2 |
| 0 |
| Children's Oncology GroupNETWORK |
| 0 |
| Aug 7, 2018 |
| clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00405327 | A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00659984 | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | completed | Phase 2 | 15 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00003513 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT00808899 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | terminated | Phase 2 | 4 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00793351 | Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation | completed | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT00960739 | Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma(MIITOP) | completed | Phase 2 | 30 | Centre Oscar LambretOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02615106 | Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma | unknown | Phase 2 | 60 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02771743 | Response-based Treatment of High-risk Neuroblastoma | unknown | Phase 2 | 54 | Samsung Medical CenterOTHER | 1 | May 24, 2016 | clinicaltrials |
| NCT01440283 | A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma | terminated | Phase 2 | 14 | St. Jude Children's Research HospitalOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 3 | Dec 3, 2015 | clinicaltrials |
| NCT00992173 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | withdrawn | Phase 2 | 0 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 2 | Nov 26, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT00874315 | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. | withdrawn | Phase 2 | 0 | Nationwide Children's HospitalOTHER | 1 | Oct 16, 2015 | clinicaltrials |
| NCT01592045 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | completed | Phase 1 / Phase 2 | 28 | United TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00030667 | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00082758 | hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 2 | Feb 12, 2015 | clinicaltrials |
| NCT00331643 | Ixabepilone in Treating Young Patients With Refractory Solid Tumors | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00098865 | Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma | completed | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | completed | Phase 2 | 101 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00311584 | Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma | completed | Phase 2 | 59 | Children's Oncology GroupNETWORK | 3 | Sep 30, 2014 | clinicaltrials |
| NCT00003461 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | completed | Phase 1 / Phase 2 | — | Duke UniversityOTHER | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00293319 | 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma | completed | Phase 2 | 164 | University of California, San FranciscoOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00003234 | Vinorelbine in Treating Children With Recurrent or Refractory Cancers | completed | Phase 2 | 50 | Children's Oncology GroupNETWORK | 7 | Jul 28, 2014 | clinicaltrials |
| NCT00003846 | Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors | completed | Phase 2 | 25 | Children's Oncology GroupNETWORK | 1 | Jul 28, 2014 | clinicaltrials |
| NCT00017368 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma | completed | Phase 2 | 42 | Children's Oncology GroupNETWORK | 2 | Feb 13, 2014 | clinicaltrials |
| NCT00084695 | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | unknown | Phase 2 | 25 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00002803 | Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma | completed | Phase 2 | 44 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00004110 | Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 31, 2013 | clinicaltrials |
| NCT00053326 | Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00281905 | Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors | unknown | Phase 2 | 50 | Children's Cancer and Leukaemia GroupOTHER | 2 | Sep 20, 2013 | clinicaltrials |
| NCT00416559 | Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only | unknown | Phase 2 | 140 | Children's Cancer and Leukaemia GroupOTHER | 0 | Sep 20, 2013 | clinicaltrials |
| NCT00003743 | Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation | unknown | Phase 2 | 25 | St. Anna KinderkrebsforschungOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00025597 | Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. | completed | Phase 2 | — | European Infant Neuroblastoma Study Group - 1999OTHER | 11 | Sep 17, 2013 | clinicaltrials |
| NCT00025610 | Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma | completed | Phase 2 | — | European Infant Neuroblastoma Study Group - 1999OTHER | 11 | Sep 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 18, 2018source: clinicaltrials